medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 6

<< Back Next >>

Ann Hepatol 2016; 15 (6)

Hepatoportal sclerosis related to the use of herbal and nutritional supplements. Causality or coincidence?

Ferreira RF, Rodrigues FLA, Codes L, Oliveira SJG, Schinoni MI, Paraná R

Language: English
References: 43
Page: 932-938
PDF size: 238.26 Kb.


ABSTRACT

Introduction and aim. Non-cirrhotic idiopathic portal hypertension (NCIPH), also known as hepatoportal sclerosis (HPS) is a disease of uncertain etiology. However, many pathophysiological mechanisms has been postulated, including thrombophilia, chronic recurrent infections and exposure to drugs or toxins. In this context, it appears to be of multifactorial etiology or resulting from a portal vascular endothelium aggression. It is important to consider whether the use of dietary supplements and herbs can trigger or contribute to the occurance of HPS. We report a possible association of HPS with the consumption of herbal and / or dietary supplements. Material and methods. We describe two cases of HPS in patients without known etiology causes associated with this disease. Results. Both patients were females who were diagnosed with HPS following the consumption of Herbalife® products and putative anorexigenic agents in the herbal infusions. Image-based analysis and the assessment of the histopathological alterations found in the livers confirmed the diagnosis. The histopatological analysis of liver samples from both patients showed portal tracts enlarged by fibrosis with disappearance or reduction in the diameter of the portal vein branches. In many portal tracts, portal veins branches were replaced by aberrant thin-walled fendiforme vessels. The bile ducts and branches of the hepatic artery show normal aspects. Conclusion. After the exclusion of other etiologic factors and a comprehensive analysis of clinical history, consumption of Herbalife® products and anorexigenic agents was pointed-out as a puttative predisposing factor for the development of the disease.


REFERENCES

  1. Garcia-Pagan JC, Groszmann R, Bosch J. Portal hypertension. In: Weinstein WM, Hawkey CJ, Bosch J (Eds.). Portal hypertension. 1st. ed. Philadelphia: Elsevier Mosby; 2005, p. 707-16.

  2. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 1071-81.

  3. De Cock KM. Hepatosplenic schistosomiasis: a clinical review. Gut 1986; 27: 734-45.

  4. Bittencourt PL, Couto CA, Ribeiro DD. Portal vein thrombosis and budd-Chiari syndrome. Hematol Oncol Clin North Am 2011; 25: 1049-66.

  5. Dunn MA, Kamel R. Hepatic schistosomiasis. Hepatology 1981; 1: 653-61.

  6. Ministério da Saúde. Esquistossomose Mansônica. Guia de Vigilância Epidemiológica. Brasília: Fundo Nacional Saúde. Ministério da Saúde; 2009.

  7. Garcia-Pagán JC, Hernández-Guerra M, Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis 2008; 28: 282-92.

  8. Datta DV. Non-cirrhotic portal fibrosis (idiopathic portal hypertension) in India. J Assoc Physicians India 1976; 24: 511-27.

  9. Kobayashi Y, Inokuchi K, Saku M. Epidemiology of idiopathic portal hypertension based on a nation-wide survey. In: Suguira M (Ed.). Report of the ministry of health and welfare research committee on idiopathic portal hypertension. Tokyo: Japan Ministry of Health and Welfare; 1976: 10-5.

  10. Mikkelsen WP, Edmondson HA, Peters RL, Redeker AG, Reynolds TB. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 1965; 162: 602-20.

  11. Aggarwal S, Fiel MI, Schiano TD. Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci 2013; 58: 2767-76.

  12. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44: 7-14.

  13. Nakanuma Y, Kouda W, Nakano T, Uneno K, Tachibana S, Araki I. A case report of early idiopathic portal hypertension. Pathol Res Pract 2001; 197: 759-63.

  14. Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol 1969; 87: 359-69.

  15. Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E, Keinan-Boker L, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007; 47: 514-20.

  16. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol 2015; 89: 851-65.

  17. Strader DB, Seeff LB. Zakim and Boyer hepatology. In: Boyer TD, Wright TL, Manns MP (Eds.). Hepatotoxicity of herbal preparations. 5th ed. Philadelphia: US Saunders – Elsevier; 2006, p. 551-60.

  18. Shad JA, Chinn CG, Brann OS. Acute hepatitis after ingestion of herbs. South Med J 1999; 92: 1095-7.

  19. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002; 177: 440-3.

  20. Stickel F. Slimming at all costs: Herbalife-induced liver injury. J Hepatol 2007; 47(4): 444-6.

  21. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-9.

  22. Andrade RJ, Lucena MI, Kaplowitz N, García-Munoz B, Borraz Y, Pachkoria K, García Cortés M, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-8.

  23. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17: 526-34.

  24. Andrade RJ, Robles M, Fernández-Castañer A, López- Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007; 13: 329-40.

  25. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.

  26. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47: 521-6.

  27. Duque JM, Ferreiro J, Salgueiro E, Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin (Barc) 2007; 128: 238-9.

  28. Chao S, Anders M, Turbay M, Olaiz E, Mc Cormack L, Mastai R. Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol Latinoam 2008; 38: 274-7.

  29. Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol 2009; 50: 111-7.

  30. Jóhannsson M, Ormarsdóttir S, Olafsson S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid 2010; 96: 167-72.

  31. Manso G, López-Rivas L, Salgueiro ME, Duque JM, Jimeno FJ, Andrade RJ, Lucena MI. Continuous reporting of new cases in Spain supports the relationship between Herbalife ® products and liver injury. Pharmacoepidemiol Drug Saf 2011; 20: 1080-7.

  32. Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987; 295: 183.

  33. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050-4.

  34. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.

  35. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11: 627-34.

  36. Nakanuma Y, Hoso M, Sasaki M, Terada T, Katayanagi K, Nonomura A, Kurumaya H, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28: 195-204.

  37. Roskams T, Baptista A, Bianchi L, Burt A, Callea F, Denk H, De Groote J, et al. Histopathology of portal hypertension: a practical guideline. Histopathology 2003; 42: 2-13.

  38. Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, Puri P, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17: 6-16.

  39. Oikawa H, Masuda T, Sato S, Yashima A, Suzuki K, Satodate R. Changes in lymph vessels and portal veins in the portal tract of patients with idiopathic portal hypertension: a morphometric study. Hepatology 1998; 27: 1607-10.

  40. Villeneuve JP, Huet PM, Joly JG, Marleau D, Côté J, Légaré A, Lafortune M, et al. Idiopathic portal hypertension. Am J Med 1976; 61: 459-64.

  41. Sama SK, Bhargava S, Nath NG, Talwar JR, Nayak NC, Tandon BN, Wig KL. Noncirrhotic portal fibrosis. Am J Med 1971; 51: 160-9.

  42. Degott C, Capron JP, Bettan L, Molas G, Bernuau D, Potet F, Feldmann G, et al. Myeloid metaplasia, perisinusoidal fibrosis, and nodular regenerative hyperplasia of the liver. Liver 1985; 5: 276-81.

  43. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Binda T, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-9.




2020     |     www.medigraphic.com